Evidation Health, a US-based digital health-focused big data technology producer, raised $15m yesterday in a series B round featuring GE Ventures, the corporate venturing arm of conglomerate General Electric.
The round was led by venture fund B Capital Group, with further participation from AMV, Fresco Capital and Pappas Ventures.
Evidation was launched in March 2015 through a partnership between GE Ventures and Stanford Health Care, the academic health system of Stanford University. The company uses big data technology to validate clinical products and services.
Evidation will use the money to scale its operations, further develop its machine learning capabilities to cope with large-scale behavioural data analytics and digital biomarker development, and to attract more customers.
GE Ventures previously contributed to a $6m series A round in January 2015 alongside Rock Health Seed Fund and Asset Management Ventures.
Deborah Kilpatrick, chief executive of Evidation Health, said: “At Evidation Health, we enable rapid evaluation of technology-based approaches that augment or replace traditional interventions – powered by direct patient participation to prove impact in the real world.
“This financing marks our fast growth and industry leadership to drive faster, better, more cost efficient ways to quantify health outcomes in the digital era of medicine.”